Floatz logo

Recombinant Human Plasma Gelsolin

Sars-CoV2

BioAegis Therapeutics Inc.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Sars-CoV2 cohort.

View all 50

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →